

1 **Adverse events of special interest for COVID-19 vaccines - background incidences vary by sex, age**
2 **and time period and are affected by the pandemic**

3 Fredrik Nyberg 1; Magnus Lindh 2,3; Lowie E.G.W. Vanfleteren 4,5; Niklas Hammar 6; Björn
4 Wettermark 7; Johan Sundström 8,9; Ailiana Santosa 1; Brian K. Kirui 1; Magnus Gisslén 2,10

5 1. School of Public Health and Community Medicine, Institute of Medicine, Sahlgrenska Academy,
6 University of Gothenburg, Gothenburg, Sweden

7 2. Department of Infectious Diseases, Institute of Biomedicine, Sahlgrenska Academy, University of
8 Gothenburg, Gothenburg, Sweden

9 3. Department of Clinical Microbiology, Sahlgrenska University Hospital, Gothenburg, Sweden

10 4. COPD Center, Department of Respiratory Medicine and Allergology, Sahlgrenska University
11 Hospital, Gothenburg, Sweden

12 5. Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska
13 Academy, University of Gothenburg, Gothenburg, Sweden

14 6. Unit of Epidemiology, Institute of Environmental Medicine, Karolinska Institute, Stockholm,
15 Sweden

16 7. Pharmacoepidemiology & Social Pharmacy, Department of Pharmacy, Uppsala University,
17 Uppsala, Sweden

18 8. Clinical Epidemiology Unit, Department of Medical Sciences, Uppsala University, Uppsala, Sweden

19 9. The George Institute for Global Health, University of New South Wales, Sydney, Australia

20 10. Region Västra Götaland, Department of Infectious Diseases, Sahlgrenska University Hospital,
21 Gothenburg, Sweden

22

23 Corresponding author:

24 Fredrik Nyberg, MPH MD PhD FISPE

25 Professor of Register Epidemiology

26 School of Public Health and Community Medicine,

27 Institute of Medicine, Sahlgrenska Academy, University of Gothenburg

28 Box 463, 405 30 Gothenburg, Sweden

29 Visiting address: Medicinaregatan 18A, Gothenburg

30 Email: Fredrik.Nyberg.2@gu.se

31 Tel: +46 31 7866289, Mobile: +46 76 6186289

32 NOTE: This preprint reports new research that has not been certified by peer review and should not
33 be used to guide clinical practice.

34

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

35 **Abstract**

36 Background

37 With large-scale COVID-19 vaccination implemented world-wide, safety signals needing rapid
38 evaluation will emerge. We report population-based, age- and-sex-specific background incidence
39 rates of conditions representing potential vaccine adverse events of special interest (AESI) for the
40 Swedish general population using register data.

41 Methods

42 We studied an age/sex-stratified random 10% sample of the Swedish population on 1 Jan 2020,
43 followed for AESI outcomes during 1 year, as the COVID-19 pandemic emerged and developed,
44 before the start of vaccinations. We selected and defined the following outcomes based on
45 information from regulatory authorities, large-scale adverse events initiatives and previous studies:
46 aseptic meningitis, febrile seizure, Kawasaki syndrome, MISC, post-infectious arthritis, arthritis,
47 myocarditis, ARDS, myocardial infarction, stroke, ischemic stroke, hemorrhagic stroke, venous
48 thromboembolism, pulmonary embolism, kidney failure, liver failure, erythema multiforme,
49 disseminated intravascular coagulation, autoimmune thyroiditis, and appendicitis. We calculated
50 incidence rates stratified by age, sex and time period (quarters of 2020), and classified them using
51 Council of International Organizations of Medical Sciences (CIOMS) categories: very common,
52 common, uncommon, rare, or very rare.

53 Results

54 We included 972,723 study subjects, representing the Swedish national population on 1 Jan 2020.
55 We found that AESI incidence rates vary greatly by age and in some cases sex. Several common AESIs
56 showed expected increase with age, while some (e.g. appendicitis, aseptic meningitis, autoimmune
57 thyroiditis, Kawasaki syndrome and MISC) were more common in young people, and others
58 exhibited a flatter age pattern (e.g. myocarditis, DIC and erythema multiforme). Consequently, the
59 CIOMS classification for AESIs varied widely according to age. Considerable variability was suggested
60 for some AESI rates across the 4 quarters of 2020, potentially related to pandemic waves, seasonal
61 variation, healthcare system overload or other healthcare delivery effects.

62 Conclusion

63 Age, sex, and timing of rates are important to consider when background AESI rates are compared to
64 corresponding rates observed with COVID-19 vaccines.

65

66 Main text

67

68 **Introduction**

69 The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) first emerged in Wuhan in
70 December 2019 (1), causing the enigmatic disease subsequently named Coronavirus disease 2019
71 (COVID-19). During 2020, the disease developed into a large-scale pandemic, spreading to most
72 countries in the world, including entering second, third or even fourth wave in many places, with
73 cumulative numbers of over 83 million cases and 1.8 million deaths reported globally during the first
74 year until end of 2020 (2). By the end of 2020, vaccines had been developed and vaccination
75 campaigns were initiated in multiple countries, including Sweden. The first COVID-19 case in Sweden
76 was reported on 31 January 2020, and in parallel with Europe becoming the epicenter for the
77 epidemic during the Spring of 2020, the disease rapidly expanded in Sweden, causing severe strain
78 on society and the healthcare system (3, 4). At the peak of the second big wave of infections,
79 vaccination was initiated in the elderly population just before the end of 2020, and has continued at
80 pace during 2021, reaching successively larger sections of the population and younger population
81 groups.

82 With the initiation of vaccination against COVID-19 in Sweden and across the world by end of 2020,
83 regulatory agencies, pharmaceutical companies, academia and other stakeholders are developing
84 safety surveillance strategies, largely based on observational data. In Europe, for instance, the
85 vACCine covid-19 monitoring readinESS (ACCESS) project funded by the European Medicines Agency
86 includes a protocol to assess background rates of conditions considered to represent potential
87 Adverse Events of Special Interest (AESI) from observational data (5). Similarly, The US FDA Center
88 for Biologics Evaluation and Research have published a protocol on “Background Rates of Adverse
89 Events of Special Interest for COVID-19 Vaccine Safety Monitoring” (6). Local background rates are
90 generally considered most appropriate for obvious reasons (7), but expected rates can also be better
91 informed by availability of background rates from many different populations, time periods and
92 areas, to understand variability and consistency of rates. Data on background rates of AESI for
93 COVID-19 vaccines from some different areas have started to appear in the scientific literature, for
94 example a multi-database study by the Observational Health Data Sciences and Informatics (OHDSI)
95 community (8). These efforts are important, as a comprehensive and thorough monitoring of vaccine
96 safety will be an essential component in addressing public concerns about the rapid COVID-19
97 vaccine development and deployment, and support efforts to address vaccine hesitancy. Here, we
98 provide descriptive epidemiology on background rates for a range of AESI in Sweden, looking at time
99 periods just prior to and during the COVID-19 pandemic, and before extensive vaccination was
100 initiated, in order to inform surveillance efforts in Sweden and internationally.

101

102 **Methods**

103 ***Study design***

104 Population-based cohort study to estimate incidence rates of conditions representing Adverse
105 Events of Special interest (AESI).

106 The analyses were based on the larger SCIFI-PEARL (Swedish Covid-19 Investigation for Future
107 Insights – a Population Epidemiology Approach using Register Linkage) project, which has been
108 described elsewhere (9). A subproject known as RECOVAC (Register-based large-scale national

109 population study to monitor Covid-19 vaccination effectiveness and safety) focuses on COVID-19
110 vaccination research questions and this analysis is a first component of that effort.

111 **Data sources**

112 The current analyses were based on the Swedish national population on 1 Jan 2020, before the
113 outbreak of the COVID-19 pandemic. The study population was identified from national registers at
114 Statistics Sweden, with age and sex data. To this study population we linked data from the National
115 Patient Register (NPR), which includes data on all hospitalizations and outpatient specialist care visits
116 in Sweden, including date of admission or date of visit and diagnoses coded with International
117 Classification of Diseases version 10 (ICD-10) codes, Swedish national version (9).

118 **Study Population and study period**

119 The study population was an age-sex stratified sample of the Swedish population as of 1 Jan 2020.
120 The number of individuals sampled and sampling fractions from the total population (i.e.
121 representing weights to obtain numbers representative for the general Swedish population) are
122 given in Suppl Table 1. The population was followed for 1 year from the index date of 1 Jan 2020, i.e.
123 during the quarter before the pandemic had spread substantially in Sweden and then during the first
124 3 quarters of pandemic spreading.

125 **Outcomes**

126 The investigated outcomes represent adverse events of special interest (AESIs) that have been
127 suggested as being particularly important to track following COVID-19 vaccination, and for which
128 there is a need to have solid information on background rates. The AESIs were identified from the
129 "Priority list of adverse events of special interest: COVID-19" AESI list by the Brighton Collaboration
130 (10), the "Background Rates of Adverse Events of Special Interest for COVID-19 Vaccine Safety
131 Monitoring" protocol published by the FDA Center for Biologics Evaluation and Research (6), and
132 lists of AESI in protocols from the EMA ACCESS project (5). Algorithms defining AESIs by ICD-10 codes
133 were developed based on these sources, some other study protocols and proposals, and a review of
134 suitable codes in the Swedish national version of ICD-10. Events were identified by ICD codes from
135 the NPR, representing hospitalization or outpatient specialist visit for the condition. Based on the
136 availability of ICD codes in our database, the following conditions could be identified with all
137 required ICD codes that we had defined: aseptic meningitis, febrile seizure, Kawasaki syndrome,
138 MISC, postinfectious arthritis, arthritis (broad definition), myocarditis, ARDS, myocardial infarction,
139 stroke, ischemic stroke, hemorrhagic stroke, venous thromboembolism, pulmonary embolism,
140 kidney failure, liver failure, erythema multiforme, disseminated intravascular coagulation,
141 autoimmune thyroiditis, appendicitis.

142 We evaluated incidence in the total population, i.e. did not require a "clean observation window" of
143 individuals with data indicating they were free of any earlier manifestation of each condition during
144 that window prior to the index start date, similar to the ACCESS protocol (5). This is also more
145 consistent with real-life vaccine monitoring, as AESIs for most conditions may occur or be
146 exacerbated in any individual, including those with earlier manifestations of the same pre-existing
147 condition. The full ICD-10 definitions used are provided in Suppl Table 2.

148 **Analysis**

149 The follow-up was evaluated for the full calendar year 2020, as well as for each quarter of 2020 (in
150 Sweden, quarter 1 was essentially pre-pandemic, quarter 2 was first wave, quarter 3 was post-wave
151 1 and quarter 4 was second wave of the pandemic; the time course of the pandemic in cases and

152 deaths is illustrated in Suppl Fig 1 as 7-day running average for COVID-19 cases and deaths over the
153 year for 2020 from our database). For each event in each time period analysis (full year or quarter),
154 individuals contributed person-time of follow-up from the start of that time period until the event
155 occurred, end of the follow-up for that time period, or death, whichever occurred first.

156 We estimated incidence rates as the number of events divided by the person-time at risk (per
157 100,000 person-years). All estimates were weighted to the age and sex distribution of the total
158 Swedish population using the sampling fractions for our population as weights. Using a similar
159 approach as ref 7, we also calculated age/sex-specific incidence rates, where age was stratified in
160 the age groups 1-5, 6-17, 18-35, 36-55, 56-64, 65-74, 75-84, and 85 years and older. All estimated
161 incidence rates, overall and age/sex-specific rates, were classified using the World Health
162 Organization Council for International Organizations of Medical Sciences (CIOMS) thresholds: very
163 common ($\geq 1/10$), common ($< 1/10$ to $\geq 1/100$), uncommon ($< 1/100$ to $\geq 1/1,000$), rare ($< 1/1,000$ to
164 $\geq 1/10,000$), and very rare ($< 1/10,000$) (12).

165 Statistical analyses were performed using the R statistical program version 4.0.2 (13).

166 ***Ethical approval***

167 The research was approved by the Swedish Ethics Review Authority, No 2020-01800, 2020-05829,
168 2021-00267, 2021-00829, 2021-02106.

169 ***Results***

170 Overall, we had information on 972,723 study subjects (480,322 men and 492,401 women) who
171 generated 957,477 person-years of follow-up during 2020 (Table 1). The corresponding weighted
172 Swedish population sample is shown in Table 1. The full age and sex distribution of the study
173 population, as well as sampling fractions from the Swedish total population, are shown in Suppl
174 Table 1.

175 The incidence rates of each AESI, overall, by sex, and stratified by age and sex are illustrated in Table
176 2. Each cell is colour-coded after the CIOMS adverse event frequency system (very common,
177 common, uncommon, rare, or very rare).

178 There is substantial variation for most AESIs by age, while sex differences are more discrete for most
179 AESIs. The age variation is clearly seen in Figure 1, where several common conditions increase as
180 expected with age, but some conditions show a different pattern. Appendicitis, aseptic meningitis,
181 autoimmune thyroiditis, Kawasaki syndrome and MISC are more common in children or younger
182 ages. Myocarditis, DIC and erythema multiforme have a more equal distribution across ages. The
183 greatest sex differences were seen for myocarditis, arthritis, autoimmune thyroiditis and ARDS.

184 In Figure 2, the incidence trend over the four quarters of 2020 is illustrated. Some AESIs, e.g. venous
185 thromboembolism, hemorrhagic stroke and postinfectious arthritis exhibit a decline in incidence
186 during the year. Some AESIs, especially ARDS and acute liver failure follow a trend with highest
187 incidence in the second and fourth quarter, corresponding approximately to wave 1 and wave 2 of
188 the COVID-19 pandemic in Sweden. Erythema multiforme shows an inverse pattern, being lower
189 during the wave 1 and 2 quarters. The MISC diagnosis was not apparent or little used before quarter
190 4, where the related diagnosis Kawasaki syndrome tended to decrease after an earlier increase
191 during the first pandemic quarter.

192 ***Discussion***

193 We report descriptive epidemiology for a number of AESIs of potential interest for safety follow-up
194 of COVID-19 vaccines, from an unselected national population. We describe baseline rates of these
195 AESIs during the year 2020 overall and by quarter. Our results illustrate a number of important
196 points for upcoming studies of vaccine safety.

197 First, the substantial variability of rates by age, and for certain outcomes also by sex, imply that it
198 will be important to have adequate demographic comparability for vaccinated and non-vaccinated
199 groups that are compared, or alternatively to ensure adequate adjustment or standardization for
200 age and sex if background rates are to be used for safety surveillance. It also means that adverse
201 event rates reported without reference to age or sex distributions will be very difficult to interpret.

202 Second, the clear trends over quarters seen for some AESI during the pandemic in Sweden, with
203 variable patterns, imply that comparing rates across appropriate time periods will be crucial. For
204 example, a doubled risk of an adverse event by a vaccine during a period when in fact the
205 background rate of that event in the underlying population as measured by healthcare encounters is
206 temporarily half of what it normally is may not be detected if a comparison is made with a historical
207 or other period when the rate is at its habitual level. Similarly, for events that are increased by the
208 infectious disease itself, e.g. MISC, if these are also increased by a vaccine, this may be difficult to
209 discern unless the comparison is made during contemporaneous time periods when the disease is
210 active. Therefore, contemporaneous studies such as the current study are essential, and it will not
211 be adequate to rely on historical background rates from literature only. Further, we found
212 substantial heterogeneity across time periods *during* the early phases of the pandemic that vaccines
213 are now used to combat, suggesting that using a single overall estimate from one selected time
214 period may be inadequate to represent the true comparator event incidence. Such patterns may
215 potentially be related to COVID-19 pandemic waves (i.e. background incidence of COVID-19),
216 seasonal variations, healthcare system overload or other healthcare-related changes during a time
217 of pandemic, e.g. changes in registration or reporting of diagnoses related to the pandemic,
218 changing consultation behaviour of patients, increasing digital healthcare delivery, or other factors.

219 For example, coagulation disorders have been associated with COVID-19 (14), and potential adverse
220 events related to coagulation disorders have recently been linked to some COVID-19 vaccines (15-
221 18). Here we report background rates for venous thromboembolism, pulmonary embolism, stroke
222 and ischemic stroke and DIC, conditions that are all relevant for this AESI category. It may be noted
223 that rates for these individual conditions have different relationships with age, as well as across the
224 4 quarters that we studied. Myocarditis is another condition that has recently been of interest as a
225 potential vaccine adverse event, particularly in younger males (19), and has been related to COVID-
226 19 (20). In our data, we see substantially higher background rates in men than women, and with a
227 tendency that the highest rates are observed in the 18-35 year age group, which will be important to
228 consider when further evaluating this potential safety issue. The rate of myocarditis was also highest
229 in the 4th quarter, during the intensive 2nd pandemic wave in Sweden, so background incidence of
230 COVID-19 over time may be quite important to consider.

231 Overall, it is comforting that despite variability and differences, our findings also show consistency
232 with prior reports from the literature on many points. Nevertheless, recent large multi-country
233 studies have shown considerable heterogeneity across populations, for example data reported from
234 the ACCESS project, which showed similar magnitudes of heterogeneity in background rates (3). The
235 pooled rates across databases from a study by the OHDSI group showed many similarities to our
236 rates for AESIs that were included in both studies; in addition, they also reported variability across
237 sites and databases (8). This further underscores that population heterogeneity needs to be taken
238 into account in the evaluation of AESIs.

239 Considering the large variability that was seen across age, sex, and time period, we would urge
240 caution when using external reference incidence rates to make comparisons with incidences
241 observed in vaccinated individuals, as the risk of systematic bias due to differences between
242 populations and situations may be substantial. Comparing incidence rates that originate from
243 different data sources may carry additional risk of systematic bias due to data-related differences
244 between data sources. Indeed, large variations have been seen between different types of data such
245 as electronic health records and claims data sources even when using harmonized type of analysis
246 and outcome definitions (8). Using rates from randomised trials or spontaneous reporting data may
247 induce even greater variability, related to the specific data collection mechanisms for these
248 activities. Overall, external rates from various sources will continue to be one important source of
249 comparator and contextual information for spontaneous adverse event reporting and estimates of
250 outcome rates in vaccinated groups of people (21-23). But this should not be considered sufficient.
251 Formal studies with contemporaneous comparators, in different databases and using appropriate
252 carefully tuned epidemiological study designs, will be essential components of adverse event
253 monitoring efforts. Fortunately, we are increasingly in a position to do this, as illustrated by the
254 SCIFI-PEARL study initiative (9) and other large-scale register data initiatives.

255 A limitation of this observational study in common with most, is that all outcomes may be subject to
256 measurement error. As all outcome definitions are based on the presence of specific ICD-10 codes
257 and were not further validated, they may lack in sensitivity or specificity, which may affect the
258 estimated incidence rates. However, as a reflection of actual healthcare encounters in the Swedish
259 healthcare system, many of these codes and algorithms have been shown to have good validity (10,
260 24). Interestingly, the existence of different patterns of misclassification in different datasets is in
261 fact a strong argument to use the same data source, population and time period for both groups
262 compared when conducting AESI evaluation. The analysis relied on data from 2020 using a target
263 population that was a defined random sample of the total Swedish population on 1 Jan 2020. This
264 provides our analysis with a good level of generalizability. We did not exclude individuals with
265 previous events of the same kind as the AESIs. This design choice is aligned with real-life concerns
266 where AESIs will be an issue whether they occur in people with or without underlying or pre-existing
267 conditions. For many conditions, rates of events are generally somewhat higher in individuals with
268 underlying comorbidity of the same type, but in most cases this difference is not very large and the
269 group with underlying comorbidity is a small minority of the total population, so that rates
270 estimated after excluding them will often only be marginally lower than rates estimated from the
271 total population. When using background incidence rates for comparison with rates in vaccinated
272 individuals it is also important to recognize that some AESIs may overlap with symptoms of the
273 infection targeted by the vaccines (in this case COVID-19), which will complicate the comparisons,
274 since the rate of infection and/or infection-related symptoms will be lower in the vaccinated
275 individuals if the vaccine is efficacious. Finally, in this study we have estimated incidence rates in
276 sub-categories of age, sex and time periods, and random variation due to small numbers should be
277 considered when interpreting the results. Nevertheless, our study overall is large and we present
278 rates “as observed” i.e. descriptively, which incorporates actual random variation in the underlying
279 data and diseases.

280 In summary, this study, which is based on high-quality Swedish healthcare register data,
281 demonstrates that there is a large variation in estimated AESI incidence rates by age and sex, as well
282 as time period in the Swedish population during 2020. While baseline rates continue to be a vital
283 reference point and analytic tool for Covid-19 vaccine monitoring (22), these results emphasize the
284 need for well-designed analytical studies with attention to stratification, standardization or
285 adjustment for age, sex and time period. These background rates provide useful real-world clinical

286 context for activities aiming at vaccine monitoring and ensuring patient safety as Covid-19 vaccines
287 are applied to combat the pandemic worldwide.

288

289 **Tables & Figures**

290 Table 1. Age and sex distribution of the sampled Swedish population

291 Table 2. Age- and sex-stratified incidence rates of 14 adverse events of special interest (AESIs) per
292 100,000 person-years (with 95% confidence intervals) in the Swedish population

293 Figure 1: Age- and sex-stratified incidence rates of 14 adverse events of special interest (AESIs) per
294 100,000 person-years (with 95% confidence intervals) in the Swedish population

295 Figure 2: Incidence rates of 14 adverse events of special interest (AESIs) per 100,000 person-years
296 (with 95% confidence intervals) in the Swedish population, by quarter of the year 2020

297

298 **Declaration of Competing Interests**

299 Dr. Nyberg reports prior employment at AstraZeneca until 2019, and ownership of some
300 AstraZeneca shares. Dr. Vanfleteren reports grants and personal fees from AstraZeneca, personal
301 fees from Novartis, GSK, Chiesi, Menarini, Pulmonx, Resmed, Boehringer, Verona Pharma, AGA Linde
302 AstraZeneca (DSMB) outside the submitted work. Dr. Sundström reports ownership in companies
303 providing services to Itrim, Amgen, Janssen, Novo Nordisk, Eli Lilly, Boehringer, Bayer, Pfizer and
304 AstraZeneca, outside the submitted work. Dr. Gisslen reports personal fees (DSMB) from
305 AstraZeneca, personal fees from Gilead, personal fees from GSK/ViiV, personal fees from MSD, other
306 from Gilead, other from GSK/ViiV, personal fees from Biogen, personal fees from Novocure, personal
307 fees from Amgen, personal fees from Novo Nordisk, outside the submitted work.

308 Dr. Lindh, Dr. Santosa, Dr. Wettermark, Dr. Hammar and Mr Kirui have nothing to disclose.

309

310 **Funding**

311 This vaccination research has received funding from Knut och Alice Wallenbergs Stiftelse / SciLifeLab
312 (KAW 2021.0010), and the Swedish Research Council (2021-05045, 2021-05450). The underlying
313 SCIFI-PEARL study is currently financed by a grants from the Swedish state under the agreement
314 between the Swedish government and the county councils, the ALF-agreement (Avtal om
315 Läkarutbildning och Forskning / Medical Training and Research Agreement) grant ALFGBG-938453
316 and from FORMAS (Forskningsrådet för miljö, areella näringar och samhällsbyggande / Research
317 Council for Environment, Agricultural Sciences and Spatial Planning), a government research council
318 for sustainable development, grant 2020-02828.

319

320 **Supplementary Materials**

321 Supplementary Table 1: Study population by age and sex, numbers and sampling fractions from
322 Swedish total population

323 Supplementary Table 2. Definitions of adverse events of interest (AESIs)

324

325 Acknowledgements

326 We acknowledge Jonatan Nåtman for statistical analysis support.

327

328 References

- 329 1. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel
330 coronavirus in Wuhan, China. *The Lancet*. 2020;395 (10223):497–506. doi:10.1016/S0140-
331 6736(20)30183-5.
- 332 2. World Health Organization. Coronavirus disease (Covid-19) Weekly Epidemiological
333 Update 5 January 2020. Available from: [https://www.who.int/emergencies/diseases/novel-](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/)
334 [coronavirus-2019/situation-reports/](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/). Accessed 6 January 2021.
- 335 3. Ludvigsson JF. The first eight months of Sweden's COVID-19 strategy and the key
336 actions and actors that were involved. *Acta Paediatr*. 2020 Dec;109(12):2459-2471. doi:
337 10.1111/apa.15582. Epub 2020 Oct 11..
- 338 4. Tegnell A. The Swedish public health response to COVID-19. *APMIS*. 2021
339 Jul;129(7):320-323. doi: 10.1111/apm.13112.
- 340 5. ACCESS: Background rates of Adverse Events of Special Interest for monitoring COVID-
341 19 vaccines. 2020. <http://www.encepp.eu/encepp/viewResource.htm?id=37274> (accessed 13 Sept
342 2021).
- 343 6. Center for Biologics Evaluation and Research Office of Biostatistics and Epidemiology.
344 CBER Surveillance Program Background Rates of Adverse Events of Special Interest for COVID-19
345 Vaccine Safety Monitoring Protocol. [https://www.bestinitiative.org/wp-](https://www.bestinitiative.org/wp-content/uploads/2021/02/C19-Vaccine-Safety-AESI-Background-Rate-Protocol-FINAL-2020.pdf)
346 [content/uploads/2021/02/C19-Vaccine-Safety-AESI-Background-Rate-Protocol-FINAL-2020.pdf](https://www.bestinitiative.org/wp-content/uploads/2021/02/C19-Vaccine-Safety-AESI-Background-Rate-Protocol-FINAL-2020.pdf)
347 (accessed 13 Sept 2021).
- 348 7. Report of CIOMS Working Group on Vaccine Safety. CIOMS Guide to Active Vaccine
349 Safety Surveillance. [https://cioms.ch/wp-content/uploads/2020/04/240WEB-CIOMS-Guide-AVSS-](https://cioms.ch/wp-content/uploads/2020/04/240WEB-CIOMS-Guide-AVSS-20170202-protected.pdf)
350 [20170202-protected.pdf](https://cioms.ch/wp-content/uploads/2020/04/240WEB-CIOMS-Guide-AVSS-20170202-protected.pdf) (accessed March 11, 2021).
- 351 8. Li X, Ostropolets A, Makadia R, Shoaibi A, Rao G, Sena AG, Martinez-Hernandez E,
352 Delmestri A, Verhamme K, Rijnbeek PR, Duarte-Salles T, Suchard M, Ryan P, Hripcsak G, Prieto-
353 Alhambra D. Characterising the background incidence rates of adverse events of special interest for
354 covid-19 vaccines in eight countries: multinational network cohort study *BMJ* 2021; 373 :n1435
355 doi:10.1136/bmj.n1435.
- 356 9. Nyberg F, Franzén S, Lindh M, Vanfleteren L, Hammar N, Wettermark B, Sundström J,
357 Santosa A, Björck S, Gisslén M. Swedish Covid-19 Investigation for Future Insights - A Population
358 Epidemiology Approach Using Register Linkage (SCIFI-PEARL). *Clin Epidemiol*. 2021;13:649-659. doi:
359 10.2147/CLEP.S312742.
- 360 10. Ludvigsson JF, Andersson E, Ekbohm A, Feychting M, Kim JL, Reuterwall C, Heurgren M,
361 Olausson PO. External review and validation of the Swedish national inpatient register. *BMC Public*
362 *Health*. 2011 Jun 9;11:450. doi: 10.1186/1471-2458-11-450.

- 363 11. Brighton Collaboration. Priority list of adverse events of special interest: COVID-19.
364 2021. <https://brightoncollaboration.us/covid-19/>; [https://brightoncollaboration.us/wp-](https://brightoncollaboration.us/wp-content/uploads/2021/01/COVID-19-updated-AESI-list.pdf)
365 [content/uploads/2021/01/COVID-19-updated-AESI-list.pdf](https://brightoncollaboration.us/wp-content/uploads/2021/01/COVID-19-updated-AESI-list.pdf) (accessed 14 Sept, 2021).
- 366 12. The Council for International Organizations of Medical Sciences (CIOMS). Guidelines
367 for Preparing Core Clinical-Safety Information on Drugs Second Edition – Report of CIOMS Working
368 Groups III and V. Geneva, 1999.
- 369 13. R Core Team (2020). R: A language and environment for statistical computing. R
370 Foundation for Statistical Computing, Vienna, Austria. <https://www.R-project.org/>.
- 371 14. Leentjens J, van Haaps TF, Wessels PF, Schutgens REG, Middeldorp S. COVID-19-
372 associated coagulopathy and antithrombotic agents-lessons after 1 year. *Lancet Haematol.* 2021
373 Jul;8(7):e524-e533. doi: 10.1016/S2352-3026(21)00105-8. Epub 2021 Apr 27.
- 374 15. Wise J. Covid-19: European countries suspend use of Oxford-AstraZeneca vaccine
375 after reports of blood clots. *BMJ* 2021; 372: n699.
- 376 16. Østergaard SD, Schmidt M, Horváth-Puhó E, Thomsen RW, Sørensen HT.
377 Thromboembolism and the Oxford-AstraZeneca COVID-19 vaccine: side-effect or coincidence?
378 *Lancet.* 2021 Apr 17;397(10283):1441-1443. doi: 10.1016/S0140-6736(21)00762-5. Epub 2021 Mar
379 30.
- 380 17. Marcucci R, Marietta M. Vaccine-induced thrombotic thrombocytopenia: the elusive
381 link between thrombosis and adenovirus-based SARS-CoV-2 vaccines. *Intern Emerg Med.* 2021
382 Aug;16(5):1113-1119. doi: 10.1007/s11739-021-02793-x. Epub 2021 Jun 30.
- 383 18. European Medicines Agency. EMA raises awareness of clinical care recommendations
384 to manage suspected thrombosis with thrombocytopenia syndrome. News 07/06/2021.
385 [https://www.ema.europa.eu/en/news/ema-raises-awareness-clinical-care-recommendations-](https://www.ema.europa.eu/en/news/ema-raises-awareness-clinical-care-recommendations-manage-suspected-thrombosis-thrombocytopenia)
386 [manage-suspected-thrombosis-thrombocytopenia](https://www.ema.europa.eu/en/news/ema-raises-awareness-clinical-care-recommendations-manage-suspected-thrombosis-thrombocytopenia). (accessed 14 Sept, 2021).
- 387 19. European Medicines Agency. Comirnaty and Spikevax: possible link to very rare cases
388 of myocarditis and pericarditis. News 09/07/2021.
389 [https://www.ema.europa.eu/en/news/comirnaty-spikevax-possible-link-very-rare-cases-](https://www.ema.europa.eu/en/news/comirnaty-spikevax-possible-link-very-rare-cases-myocarditis-pericarditis)
390 [myocarditis-pericarditis](https://www.ema.europa.eu/en/news/comirnaty-spikevax-possible-link-very-rare-cases-myocarditis-pericarditis). (accessed 14 Sept, 2021).
- 391 20. Boehmer TK, Kompaniyets L, Lavery AM, Hsu J, Ko JY, Yusuf H, Romano SD, Gundlapalli
392 AV, Oster ME, Harris AM. Association Between COVID-19 and Myocarditis Using Hospital-Based
393 Administrative Data - United States, March 2020-January 2021. *MMWR Morb Mortal Wkly Rep.*
394 2021 Sep 3;70(35):1228-1232. doi: 10.15585/mmwr.mm7035e5.
- 395 21. Black S, Eskola J, Siegrist C-A, et al. Importance of background rates of disease in
396 assessment of vaccine safety during mass immunisation with pandemic H1N1 influenza vaccines.
397 *Lancet* 2009; 374: 2115–22.
- 398 22. Rasmussen TA, Jørgensen MRS, Bjerrum S, et al. Use of population based background
399 rates of disease to assess vaccine safety in childhood and mass immunisation in Denmark:
400 nationwide population based cohort study. *BMJ* 2012; 345: e5823.
- 401 23. Black SB, Law B, Chen RT, et al. The critical role background rates of possible adverse
402 events in the assessment of COVID-19 vaccine safety. *Vaccine* 2021; published online March.
403 DOI:10.1016/j.vaccine.2021.03.016.

404 24. Friberg L, Skeppholm M. Usefulness of Health Registers for detection of bleeding
405 events in outcome studies. *Thromb Haemost* 2016; 116(06): 1131-1139. DOI: 10.1160/TH16-05-
406 0400.

Table 1. Age and sex distribution of the sampled Swedish population


	Men	Women	Total
n	480322	492401	972723
n weighted*	489377.5	483345.6	972723.1
person-years	472663.8	484813.3	957477.0
person-years weighted*	487099.8	481010.4	968110.2
Age group, weighted n (%)*			
0-5 years	35200.3 (7.2)	33206.4 (6.9)	
6-17 years	70503.7 (14.4)	66464.8 (13.8)	
18-35 years	117151.5 (23.9)	108807.4 (22.5)	
36-55 years	126170.4 (25.8)	121726.6 (25.2)	
56-64 years	49777.7 (10.2)	49183.9 (10.2)	
65-74 years	50908.0 (10.4)	52741.1 (10.9)	
75-84 years	30783.2 (6.3)	35302.8 (7.3)	
85+ years	8882.7 (1.8)	15912.6 (3.3)	

* Sample weighted to the age/sex structure of the Swedish population

Table 2: Age- and sex-stratified incidence rates per 100,00 person-years (with 95% confidence intervals), colour-coded by CIOMS frequency classification*

	sex	Age groups, years								total
		0-5	6-17	18-35	36-55	56-64	65-74	75-84	85+	
Arthritis (all types)	Female	186.4 (137.2, 235.6)	244.8 (205.4, 284.2)	378.1 (337.4, 418.8)	790.9 (735.8, 846.0)	1428.2 (1317.2, 1539.1)	1937.9 (1815.8, 2060.0)	2204.0 (2071.0, 2337.1)	1145.7 (1051.1, 1240.3)	886.3 (859.3, 913.2)
Arthritis (all types)	Male	247.1 (190.5, 303.7)	159.8 (127.9, 191.8)	151.7 (125.9, 177.5)	385.6 (347.1, 424.0)	739.4 (659.7, 819.2)	998.2 (910.4, 1086.1)	1279.2 (1176.1, 1382.2)	804.1 (719.4, 888.8)	450.6 (431.4, 469.8)
Myocardial infarction	Female	0.000 (0.000, 0.000)	0.000 (0.000, 0.000)	2.23 (0.000, 5.34)	27.3 (17.0, 37.6)	125.7 (92.8, 158.6)	336.3 (285.2, 387.4)	704.2 (630.1, 778.3)	1299.7 (1205.3, 1394.2)	151.1 (141.7, 160.5)
Myocardial infarction	Male	0.000 (0.000, 0.000)	0.000 (0.000, 0.000)	8.18 (2.11, 14.2)	118.6 (97.2, 139.9)	478.0 (414.1, 541.9)	723.3 (648.6, 798.1)	1161.6 (1064.0, 1259.2)	1875.9 (1752.4, 1999.4)	263.5 (250.2, 276.8)
Stroke	Female	10.2 (0.000, 21.6)	9.84 (1.96, 17.7)	18.3 (9.31, 27.3)	72.5 (55.7, 89.2)	247.8 (201.5, 294.1)	480.0 (419.0, 540.9)	1143.0 (1049.2, 1236.9)	2172.7 (2050.7, 2294.8)	257.0 (244.7, 269.4)
Stroke	Male	23.7 (6.14, 41.2)	8.29 (1.02, 15.6)	27.9 (16.9, 38.8)	121.6 (99.9, 143.2)	389.7 (331.9, 447.6)	865.1 (783.2, 947.0)	1776.5 (1658.2, 1894.7)	2824.3 (2671.6, 2977.0)	333.6 (319.0, 348.1)
Ischemic stroke	Female	3.38 (0.000, 10.0)	6.52 (0.128, 12.9)	5.16 (0.624, 9.69)	45.4 (32.1, 58.6)	180.5 (141.0, 220.1)	356.6 (304.0, 409.2)	901.5 (817.8, 985.2)	1772.0 (1661.5, 1882.5)	195.2 (184.6, 205.8)
Ischemic stroke	Male	6.76 (0.000, 16.1)	3.25 (0.000, 7.76)	18.4 (9.38, 27.5)	86.3 (68.1, 104.5)	310.8 (259.2, 362.4)	654.5 (583.3, 725.8)	1368.1 (1263.7, 1472.5)	2097.7 (1965.6, 2229.8)	251.5 (238.8, 264.1)
Acute kidney injury	Female	3.38 (0.000, 10.0)	1.61 (0.000, 4.75)	17.9 (9.08, 26.7)	40.4 (27.9, 52.9)	92.3 (64.0, 120.5)	259.5 (214.6, 304.4)	707.0 (632.8, 781.2)	1306.3 (1211.5, 1401.1)	147.0 (137.7, 156.2)
Acute kidney injury	Male	20.3 (4.06, 36.5)	4.96 (0.000, 10.6)	15.4 (7.29, 23.5)	74.3 (57.4, 91.3)	292.1 (241.9, 342.3)	531.5 (467.3, 595.7)	1163.6 (1067.8, 1259.4)	2239.9 (2105.0, 2374.8)	223.9 (212.1, 235.6)
Pulmonary embolism	Female	0.000 (0.000, 0.000)	9.63 (1.93, 17.3)	46.6 (32.4, 60.8)	72.0 (55.4, 88.7)	178.1 (138.8, 217.3)	341.9 (290.5, 393.4)	619.7 (549.7, 689.8)	657.2 (587.6, 726.7)	152.3 (141.9, 162.7)
Pulmonary embolism	Male	0.000 (0.000, 0.000)	3.25 (0.000, 7.76)	22.7 (12.7, 32.7)	92.0 (73.2, 110.8)	271.2 (222.9, 319.5)	413.2 (356.6, 469.8)	579.4 (510.3, 648.5)	667.1 (592.2, 742.1)	148.8 (138.3, 159.2)
Appendicitis	Female	16.9 (2.09, 31.8)	165.6 (133.2, 198.0)	168.2 (141.4, 195.0)	136.6 (113.7, 159.4)	93.3 (64.7, 121.8)	65.9 (43.4, 88.4)	71.9 (47.1, 96.7)	51.1 (31.0, 71.2)	119.8 (109.4, 130.2)
Appendicitis	Male	40.6 (17.6, 63.5)	207.8 (171.2, 244.3)	190.4 (161.9, 219.0)	108.4 (88.1, 128.7)	107.5 (77.1, 137.9)	98.9 (71.2, 126.6)	80.9 (54.5, 107.3)	56.8 (34.2, 79.4)	133.7 (122.5, 144.9)
ARDS	Female	0.000 (0.000, 0.000)	0.000 (0.000, 0.000)	2.18 (0.000, 5.21)	13.1 (5.96, 20.2)	36.2 (18.4, 53.9)	32.3 (16.4, 48.1)	47.1 (27.6, 66.7)	27.8 (15.0, 40.6)	15.3 (11.9, 18.8)
ARDS	Male	3.38 (0.000, 10.0)	0.000 (0.000, 0.000)	10.4 (3.57, 17.1)	36.3 (24.4, 48.1)	78.6 (52.6, 104.7)	108.9 (79.9, 137.9)	103.0 (75.0, 131.1)	48.8 (28.6, 69.1)	38.8 (33.1, 44.4)
Haemorrhagic stroke	Female	6.77 (0.000, 16.2)	1.71 (0.000, 5.06)	13.2 (5.38, 21.0)	30.1 (19.3, 40.9)	74.1 (48.8, 99.4)	126.9 (95.6, 158.2)	263.3 (218.3, 308.2)	413.4 (359.6, 467.2)	65.5 (58.9, 72.1)
Haemorrhagic stroke	Male	13.5 (0.271, 26.8)	5.04 (0.000, 10.7)	10.6 (4.03, 17.3)	36.3 (24.4, 48.1)	87.6 (60.1, 115.1)	229.3 (187.1, 271.5)	438.8 (380.3, 497.4)	747.0 (668.0, 826.0)	87.5 (80.0, 95.0)
Postinfectious arthritis	Female	6.77 (0.000, 16.2)	6.73 (0.133, 13.3)	10.6 (4.00, 17.2)	14.1 (6.70, 21.5)	22.7 (8.61, 36.7)	18.3 (6.33, 30.2)	18.8 (6.97, 30.7)	28.6 (14.1, 43.0)	13.9 (10.5, 17.3)
Postinfectious arthritis	Male	23.7 (6.14, 41.2)	4.96 (0.000, 10.6)	21.0 (11.5, 30.5)	18.0 (9.67, 26.3)	31.6 (15.0, 48.1)	28.2 (13.4, 42.9)	35.3 (18.0, 52.6)	36.3 (19.0, 53.5)	21.1 (16.8, 25.4)
Autoimmune thyroiditis	Female	0.000 (0.000, 0.000)	91.3 (67.4, 115.2)	45.7 (31.3, 60.1)	44.6 (31.6, 57.6)	36.4 (18.6, 54.3)	25.9 (11.8, 40.0)	22.6 (8.46, 36.7)	2.25 (0.000, 6.67)	42.3 (36.1, 48.6)
Autoimmune thyroiditis	Male	0.000 (0.000, 0.000)	23.0 (11.0, 35.1)	8.12 (2.09, 14.1)	10.9 (4.45, 17.3)	6.65 (0.000, 14.2)	6.10 (0.000, 13.0)	10.7 (1.08, 20.4)	3.75 (0.000, 9.26)	10.1 (7.06, 13.2)
Venous thromboembolism	Female	0.000 (0.000, 0.000)	3.21 (0.000, 7.66)	11.8 (4.46, 19.1)	22.9 (13.5, 32.3)	47.6 (27.3, 68.0)	44.5 (25.9, 63.1)	88.4 (61.2, 115.5)	54.7 (35.0, 74.3)	26.8 (22.2, 31.4)
Venous thromboembolism	Male	0.000 (0.000, 0.000)	4.88 (0.000, 10.4)	11.7 (4.43, 19.0)	27.9 (17.6, 38.3)	38.4 (20.1, 56.6)	54.6 (34.0, 75.2)	78.4 (53.0, 103.7)	59.0 (36.5, 81.6)	26.3 (21.6, 30.9)
Acute Liver failure	Female	0.000 (0.000, 0.000)	0.000 (0.000, 0.000)	1.98 (0.000, 4.74)	7.13 (1.85, 12.4)	18.0 (5.52, 30.5)	42.2 (24.1, 60.3)	46.4 (27.1, 65.6)	22.2 (9.03, 35.3)	12.8 (9.66, 15.9)
Acute Liver failure	Male	3.38 (0.000, 10.0)	0.000 (0.000, 0.000)	5.73 (0.698, 10.8)	12.0 (5.20, 18.8)	35.9 (18.3, 53.5)	68.5 (45.5, 91.5)	96.2 (67.6, 124.8)	78.2 (51.7, 104.7)	23.0 (18.8, 27.1)
Myocarditis	Female	3.38 (0.000, 10.0)	8.03 (0.992, 15.1)	9.12 (2.77, 15.5)	6.03 (1.20, 10.9)	6.54 (0.000, 14.0)	4.16 (0.000, 9.92)	11.5 (2.14, 20.8)	6.21 (1.24, 11.2)	7.07 (4.59, 9.54)
Myocarditis	Male	0.000 (0.000, 0.000)	11.4 (2.95, 19.8)	33.1 (21.4, 44.7)	21.9 (12.7, 31.0)	24.8 (10.1, 39.4)	20.2 (7.68, 32.7)	20.5 (7.41, 33.5)	27.6 (12.3, 42.8)	21.6 (17.2, 26.0)
Febrile seizure	Female	261.1 (202.8, 319.3)	3.42 (0.000, 8.15)	0.000 (0.000, 0.000)	0.000 (0.000, 0.000)	0.000 (0.000, 0.000)	0.000 (0.000, 0.000)	1.66 (0.000, 4.92)	0.000 (0.000, 0.000)	18.5 (14.5, 22.6)
Febrile seizure	Male	267.5 (208.6, 326.4)	6.83 (0.137, 13.5)	0.000 (0.000, 0.000)	0.000 (0.000, 0.000)	0.000 (0.000, 0.000)	0.000 (0.000, 0.000)	0.000 (0.000, 0.000)	0.000 (0.000, 0.000)	20.2 (15.9, 24.6)
Aseptic meningitis	Female	0.000 (0.000, 0.000)	1.61 (0.000, 4.75)	11.0 (4.15, 17.9)	0.971 (0.000, 2.88)	0.000 (0.000, 0.000)	0.000 (0.000, 0.000)	0.000 (0.000, 0.000)	0.000 (0.000, 0.000)	2.94 (1.27, 4.61)
Aseptic meningitis	Male	6.76 (0.000, 16.1)	3.42 (0.000, 8.15)	4.56 (0.081, 9.05)	7.01 (1.82, 12.2)	2.32 (0.000, 6.87)	0.000 (0.000, 0.000)	0.000 (0.000, 0.000)	0.000 (0.000, 0.000)	4.11 (2.09, 6.13)
Erythema multiforme	Female	0.000 (0.000, 0.000)	0.000 (0.000, 0.000)	5.40 (0.643, 10.2)	1.99 (0.000, 4.75)	6.96 (0.000, 14.8)	12.1 (2.42, 21.8)	9.05 (1.01, 17.1)	1.03 (0.000, 3.06)	4.45 (2.51, 6.38)
Erythema multiforme	Male	6.76 (0.000, 16.1)	6.67 (0.132, 13.2)	3.04 (0.000, 6.47)	2.93 (0.000, 6.24)	4.49 (0.000, 10.7)	8.00 (0.161, 15.8)	9.73 (0.932, 18.5)	3.75 (0.000, 9.26)	4.90 (2.87, 6.93)
Kawasaki's syndrome	Female	20.3 (4.06, 36.6)	4.92 (0.000, 10.5)	0.000 (0.000, 0.000)	0.000 (0.000, 0.000)	0.000 (0.000, 0.000)	0.000 (0.000, 0.000)	0.000 (0.000, 0.000)	0.000 (0.000, 0.000)	2.07 (0.718, 3.43)
Kawasaki's syndrome	Male	23.7 (6.14, 41.2)	8.37 (1.03, 15.7)	2.02 (0.000, 4.83)	0.000 (0.000, 0.000)	0.000 (0.000, 0.000)	0.000 (0.000, 0.000)	0.000 (0.000, 0.000)	0.000 (0.000, 0.000)	3.39 (1.62, 5.17)
MISC	Female	0.000 (0.000, 0.000)	6.63 (0.130, 13.1)	0.000 (0.000, 0.000)	0.000 (0.000, 0.000)	0.000 (0.000, 0.000)	0.000 (0.000, 0.000)	1.66 (0.000, 4.92)	0.000 (0.000, 0.000)	1.03 (0.108, 1.96)
MISC	Male	3.38 (0.000, 10.0)	0.000 (0.000, 0.000)	0.000 (0.000, 0.000)	0.000 (0.000, 0.000)	2.32 (0.000, 6.87)	2.00 (0.000, 5.92)	2.55 (0.000, 7.55)	0.000 (0.000, 0.000)	0.848 (0.007, 1.69)
Disseminated intravascular coagulation	Female	0.000 (0.000, 0.000)	3.31 (0.000, 7.91)	1.19 (0.000, 3.51)	0.000 (0.000, 0.000)	0.000 (0.000, 0.000)	3.93 (0.000, 9.39)	0.000 (0.000, 0.000)	1.03 (0.000, 3.06)	1.19 (0.170, 2.20)
Disseminated intravascular coagulation	Male	0.000 (0.000, 0.000)	1.71 (0.000, 5.05)	1.22 (0.000, 3.63)	0.000 (0.000, 0.000)	2.17 (0.000, 6.41)	2.05 (0.000, 6.06)	1.54 (0.000, 4.57)	0.000 (0.000, 0.000)	1.07 (0.090, 2.05)

* CIOMS: Council of International Organizations of Medical Sciences






Figure 1




Figure 2